Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1982 Mar;21(3):428-35.
doi: 10.1128/AAC.21.3.428.

Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment

Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment

A Mangione et al. Antimicrob Agents Chemother. 1982 Mar.

Abstract

The dose dependence of mezlocillin pharmacokinetics was examined in relation to renal function after intravenous doses of 1 and 5 g in 16 subjects with various degrees of renal impairment. Dose and time-average model-independent physiological parameters were calculated from plasma concentration and urinary excretion data. Lack of superimposition of plasma concentration profiles occurred between dosage levels with a twofold exaggeration of areas under the curve produced between doses of 1 and 5 g. Decreased plasma clearances at the higher dose were caused partly by nonlinear renal clearance, but more markedly by dose dependence in nonrenal clearances. At each dosage level, these parameters were examined in relation to creatinine clearances. Plasma and renal clearances exhibited a typical linear correlation with creatinine clearance for each dose level. However, nonrenal clearances demonstrated a linear relationship with creatinine clearance at the 1-g dose, but apparent saturation of this pathway produced lower and relatively constant nonrenal clearance values at the 5-g dose. Mezlocillin pharmacokinetics are thus influenced by both dose and renal function over the dosage range of 1 to 5 g. Saturation in renal clearance and probably in biliary clearance explains the unusual disposition characteristics of mezlocillin observed in this and previously reported studies.

PubMed Disclaimer

References

    1. Appl Microbiol. 1966 Mar;14(2):170-7 - PubMed
    1. J Pharm Sci. 1969 Sep;58(9):1106-9 - PubMed
    1. Clin Chim Acta. 1974 Jan 19;50(1):13-8 - PubMed
    1. J Pharmacokinet Biopharm. 1976 Oct;4(5):443-67 - PubMed
    1. J Pharm Pharmacol. 1978 Aug;30(8):508-9 - PubMed

Publication types